Elicio Therapeutics, Inc.
ELTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $283 | $0 | $278 | $305 |
| Gross Profit | -$283 | $0 | -$278 | -$305 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,990 | $7,006 | $7,778 | $10,624 |
| G&A Expenses | $0 | $3,085 | $2,958 | $0 |
| SG&A Expenses | $2,772 | $3,085 | $2,958 | $2,547 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$278 | $0 |
| Operating Expenses | $7,762 | $10,091 | $10,458 | $13,171 |
| Operating Income | -$8,045 | -$10,091 | -$10,736 | -$13,476 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2,038 | -$470 | -$473 | -$528 |
| Pre-Tax Income | -$10,083 | -$10,561 | -$11,209 | -$14,004 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10,083 | -$10,561 | -$11,209 | -$14,004 |
| % Margin | – | – | – | – |
| EPS | -0.6 | -0.66 | -0.87 | -1.15 |
| % Growth | 9.1% | 24.1% | 24.3% | – |
| EPS Diluted | -0.6 | -0.66 | -0.87 | -1.15 |
| Weighted Avg Shares Out | 16,692 | 16,059 | 12,951 | 12,203 |
| Weighted Avg Shares Out Dil | 16,692 | 16,059 | 12,951 | 12,203 |
| Supplemental Information | – | – | – | – |
| Interest Income | $199 | $168 | $210 | $305 |
| Interest Expense | $426 | $194 | $176 | $234 |
| Depreciation & Amortization | $283 | $281 | $278 | $305 |
| EBITDA | -$9,374 | -$10,086 | -$10,755 | -$13,465 |
| % Margin | – | – | – | – |